Unilever looks set to beat out Nestle in the bidding war for GlaxoSmithKline’s Indian nutrition business. The acquisition would bring less than $4bn to Unilever but would strengthen the company’s position in Indian markets, which are currently showing faster growth than Western markets. “India is a very important market and we have been working on this deal since last year,” said Mr Gulati. Horlicks’ growth has slowed from 15% to 4% between 2013 and 2017.
Unilever looks set to beat out Nestle in the bidding war for GlaxoSmithKline’s Indian nutrition business. The acquisition would bring less than $4bn to Unilever but would strengthen the company’s position in Indian markets, which are currently showing faster growth than Western markets. Horlicks, one of Glaxo India's leading products, dominates India’s nutritional drinks market, which could see a slowdown in growth. Horlicks’ growth has slowed from 15% to 4% between 2013 and 2017.